Overview
- The Series A financing was co-led by 5AM Ventures, OrbiMed and Monograph Capital, with investor representatives joining the board.
- Prolynx is developing extended-duration incretin and non-incretin peptides intended for once-monthly or once-quarterly dosing.
- Its half-life extension approach uses proprietary chemical linkers to deliver controlled release, which the company says has previously shown clinical proof-of-concept in oncology.
- Early plans include a longer-acting semaglutide and additional GLP-1/GIP and amylin programs, with a regulatory strategy that builds on existing data, including use of the FDA’s 505(b)(2) pathway.
- The company has not disclosed when it expects to begin clinical testing of its experimental medicines.